We serve Chemical Name:D-myo-Inositol-1,3,4,5-tetrakisphosphate, octapotassium salt CAS:135269-51-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:D-myo-Inositol-1,3,4,5-tetrakisphosphate, octapotassium salt
CAS.NO:135269-51-1
Synonyms:D-myo-Inositol 1,3,4,5-tetrakis(phosphate) potassium salt;MFCD00171286;D-MYO-INOSITOL 1,3,4,5-TETRAKIS-*PHOSPHA TE POTASSIU;D-MYO-INOSITOL 1,3,4,5-TETRAKIS-PHOSPHATE POTASSIUM SALT;D-MYO-INOSITOL 1,3,4,5-TETRAPHOSPHATE POTASSIUM SALT;D-myo-Inositol,1,3,4,5-Tetrakisphosphate,Octapotassium Sat;D-myo-inositol 1,3,4,5-tetrakis-*phosphate potass
Molecular Formula:C6H15KO18P4
Molecular Weight:538.16600
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:349.57000
Exact Mass:537.88500
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like D-myo-Inositol 1,3,4,5-tetrakis(phosphate) potassium salt chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,D-myo-inositol 1,3,4,5-tetrakis-*phosphate potass physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,D-MYO-INOSITOL 1,3,4,5-TETRAKIS-PHOSPHATE POTASSIUM SALT Use and application,D-MYO-INOSITOL 1,3,4,5-TETRAKIS-PHOSPHATE POTASSIUM SALT technical grade,usp/ep/jp grade.
Related News: The site’s workforce currently stands 550-strong. Takeda plans to boost its headcount in Thousand Oaks, though nothing is certain, Hatke said, as quoted by the Business Times. [4,5-diacetyloxy-7-(hydroxymethyl)-9,10-dioxoanthracen-2-yl] acetate manufacturers Throughout the pandemic, our site remained fully operational while keeping our employees safe and having a positive impact on human health. Our expanded facility will provide us with the increased capacity needed to continue the essential services we provide to our clients” 1-(2-chloro-benzoyl)-3-(6-methyl-5-o-tolyl-pyrazin-2-yl)-urea suppliers SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. (4-Methoxymethoxy-3-methyl-6-phenyl-benzofuran-2-yl)-pyrimidin-5-yl-methanone vendor & factory.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. (4-Methoxymethoxy-3-methyl-6-phenyl-benzofuran-2-yl)-pyrimidin-5-yl-methanone vendor & factory.
